Donanemab Studied in Early Symptomatic Alzheimer Disease
Slightly less cognitive and functional decline seen with donanemab versus placebo at 76 weeks in phase 2 trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.